Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes

Ryotaro Bouchi, Tatsuya Fukuda, Takato Takeuchi, Yujiro Nakano, Masanori Murakami, Isao Minami, Hajime Izumiyama, Koshi Hashimoto, Takanobu Yoshimoto, Yoshihiro Ogawa

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Activation of dipeptidyl peptidase 4 has been reported to be associated with impairment of insulin signalling in skeletal muscle, presumably leading to loss of muscle function. This study was aimed to investigate whether the use of dipeptidyl peptidase 4 inhibitors (DPP4i) could attenuate the progressive loss of muscle mass in patients with type 2 diabetes. Methods: A total 105 patients with type 2 diabetes (mean age 62 ± 12 years; 39% female) were studied in this retrospective observational study. To reduce the bias due to confounding variables, propensity-score matching analysis was performed. Change in skeletal muscle index measured by the whole body dual-energy X-ray absorptiometry at 1-year follow-up was evaluated. One-year changes in visceral and subcutaneous fat area and liver attenuation index were also determined by abdominal computed tomography. Results: Overall, 37 of 105 (35.2%) patients were treated with DPP4i. The estimated change in skeletal muscle index in patients with DPP4i was significantly higher than that in patients without (0.05 ± 0.06 vs −0.10 ± 0.04 kg, P =.046). In a propensity-matched population (N = 48), the same finding was observed (0.04 ± 0.03 in DPP4i versus −0.12 ± 0.03 kg in non-DPP4i, P =.033). There were no significant differences in changes of visceral and subcutaneous fat area and liver attenuation index between patients with DPP4i and those without. Conclusions: Our data suggest the potential of DPP4i to prevent the progressive loss of muscle mass with ageing in patients with type 2 diabetes.

Original languageEnglish
Article numbere2957
JournalDiabetes/Metabolism Research and Reviews
Volume34
Issue number2
DOIs
Publication statusPublished - Feb 1 2018
Externally publishedYes

Fingerprint

Dipeptidyl-Peptidase IV Inhibitors
Type 2 Diabetes Mellitus
Skeletal Muscle
Intra-Abdominal Fat
Subcutaneous Fat
Muscles
Dipeptidyl Peptidase 4
Propensity Score
Confounding Factors (Epidemiology)
Liver
Photon Absorptiometry
Protease Inhibitors
Observational Studies
Retrospective Studies
Tomography
Insulin

All Science Journal Classification (ASJC) codes

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. / Bouchi, Ryotaro; Fukuda, Tatsuya; Takeuchi, Takato; Nakano, Yujiro; Murakami, Masanori; Minami, Isao; Izumiyama, Hajime; Hashimoto, Koshi; Yoshimoto, Takanobu; Ogawa, Yoshihiro.

In: Diabetes/Metabolism Research and Reviews, Vol. 34, No. 2, e2957, 01.02.2018.

Research output: Contribution to journalArticle

Bouchi, R, Fukuda, T, Takeuchi, T, Nakano, Y, Murakami, M, Minami, I, Izumiyama, H, Hashimoto, K, Yoshimoto, T & Ogawa, Y 2018, 'Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes', Diabetes/Metabolism Research and Reviews, vol. 34, no. 2, e2957. https://doi.org/10.1002/dmrr.2957
Bouchi, Ryotaro ; Fukuda, Tatsuya ; Takeuchi, Takato ; Nakano, Yujiro ; Murakami, Masanori ; Minami, Isao ; Izumiyama, Hajime ; Hashimoto, Koshi ; Yoshimoto, Takanobu ; Ogawa, Yoshihiro. / Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes. In: Diabetes/Metabolism Research and Reviews. 2018 ; Vol. 34, No. 2.
@article{c475da53240e48819f879ea4e013d67f,
title = "Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes",
abstract = "Background: Activation of dipeptidyl peptidase 4 has been reported to be associated with impairment of insulin signalling in skeletal muscle, presumably leading to loss of muscle function. This study was aimed to investigate whether the use of dipeptidyl peptidase 4 inhibitors (DPP4i) could attenuate the progressive loss of muscle mass in patients with type 2 diabetes. Methods: A total 105 patients with type 2 diabetes (mean age 62 ± 12 years; 39{\%} female) were studied in this retrospective observational study. To reduce the bias due to confounding variables, propensity-score matching analysis was performed. Change in skeletal muscle index measured by the whole body dual-energy X-ray absorptiometry at 1-year follow-up was evaluated. One-year changes in visceral and subcutaneous fat area and liver attenuation index were also determined by abdominal computed tomography. Results: Overall, 37 of 105 (35.2{\%}) patients were treated with DPP4i. The estimated change in skeletal muscle index in patients with DPP4i was significantly higher than that in patients without (0.05 ± 0.06 vs −0.10 ± 0.04 kg, P =.046). In a propensity-matched population (N = 48), the same finding was observed (0.04 ± 0.03 in DPP4i versus −0.12 ± 0.03 kg in non-DPP4i, P =.033). There were no significant differences in changes of visceral and subcutaneous fat area and liver attenuation index between patients with DPP4i and those without. Conclusions: Our data suggest the potential of DPP4i to prevent the progressive loss of muscle mass with ageing in patients with type 2 diabetes.",
author = "Ryotaro Bouchi and Tatsuya Fukuda and Takato Takeuchi and Yujiro Nakano and Masanori Murakami and Isao Minami and Hajime Izumiyama and Koshi Hashimoto and Takanobu Yoshimoto and Yoshihiro Ogawa",
year = "2018",
month = "2",
day = "1",
doi = "10.1002/dmrr.2957",
language = "English",
volume = "34",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Dipeptidyl peptidase 4 inhibitors attenuates the decline of skeletal muscle mass in patients with type 2 diabetes

AU - Bouchi, Ryotaro

AU - Fukuda, Tatsuya

AU - Takeuchi, Takato

AU - Nakano, Yujiro

AU - Murakami, Masanori

AU - Minami, Isao

AU - Izumiyama, Hajime

AU - Hashimoto, Koshi

AU - Yoshimoto, Takanobu

AU - Ogawa, Yoshihiro

PY - 2018/2/1

Y1 - 2018/2/1

N2 - Background: Activation of dipeptidyl peptidase 4 has been reported to be associated with impairment of insulin signalling in skeletal muscle, presumably leading to loss of muscle function. This study was aimed to investigate whether the use of dipeptidyl peptidase 4 inhibitors (DPP4i) could attenuate the progressive loss of muscle mass in patients with type 2 diabetes. Methods: A total 105 patients with type 2 diabetes (mean age 62 ± 12 years; 39% female) were studied in this retrospective observational study. To reduce the bias due to confounding variables, propensity-score matching analysis was performed. Change in skeletal muscle index measured by the whole body dual-energy X-ray absorptiometry at 1-year follow-up was evaluated. One-year changes in visceral and subcutaneous fat area and liver attenuation index were also determined by abdominal computed tomography. Results: Overall, 37 of 105 (35.2%) patients were treated with DPP4i. The estimated change in skeletal muscle index in patients with DPP4i was significantly higher than that in patients without (0.05 ± 0.06 vs −0.10 ± 0.04 kg, P =.046). In a propensity-matched population (N = 48), the same finding was observed (0.04 ± 0.03 in DPP4i versus −0.12 ± 0.03 kg in non-DPP4i, P =.033). There were no significant differences in changes of visceral and subcutaneous fat area and liver attenuation index between patients with DPP4i and those without. Conclusions: Our data suggest the potential of DPP4i to prevent the progressive loss of muscle mass with ageing in patients with type 2 diabetes.

AB - Background: Activation of dipeptidyl peptidase 4 has been reported to be associated with impairment of insulin signalling in skeletal muscle, presumably leading to loss of muscle function. This study was aimed to investigate whether the use of dipeptidyl peptidase 4 inhibitors (DPP4i) could attenuate the progressive loss of muscle mass in patients with type 2 diabetes. Methods: A total 105 patients with type 2 diabetes (mean age 62 ± 12 years; 39% female) were studied in this retrospective observational study. To reduce the bias due to confounding variables, propensity-score matching analysis was performed. Change in skeletal muscle index measured by the whole body dual-energy X-ray absorptiometry at 1-year follow-up was evaluated. One-year changes in visceral and subcutaneous fat area and liver attenuation index were also determined by abdominal computed tomography. Results: Overall, 37 of 105 (35.2%) patients were treated with DPP4i. The estimated change in skeletal muscle index in patients with DPP4i was significantly higher than that in patients without (0.05 ± 0.06 vs −0.10 ± 0.04 kg, P =.046). In a propensity-matched population (N = 48), the same finding was observed (0.04 ± 0.03 in DPP4i versus −0.12 ± 0.03 kg in non-DPP4i, P =.033). There were no significant differences in changes of visceral and subcutaneous fat area and liver attenuation index between patients with DPP4i and those without. Conclusions: Our data suggest the potential of DPP4i to prevent the progressive loss of muscle mass with ageing in patients with type 2 diabetes.

UR - http://www.scopus.com/inward/record.url?scp=85035104466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85035104466&partnerID=8YFLogxK

U2 - 10.1002/dmrr.2957

DO - 10.1002/dmrr.2957

M3 - Article

C2 - 29054111

AN - SCOPUS:85035104466

VL - 34

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 2

M1 - e2957

ER -